Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study

Clicks: 1
ID: 324136
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #157 of 197 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Immune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis. METHODS: Pregnancies to women with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), spondyloarthritis (SpA) and inflammatory bowel disease (IBD) were identified within the Clinical Practice Research Datalink, between 01-Jan-2000 and 31-Jun-2020, and matched to pregnancies in women with no such diagnosis. Drug prescribing patterns were described during and surrounding pregnancy. The risk of spontaneous pregnancy loss and major congenital malformations (MCMs) were evaluated compared to women without an IMID. Exposure to commonly prescribed disease-modifying anti-rheumatic drugs was evaluated. RESULTS: The risk of a spontaneous pregnancy loss ranged from HRadj 1.01 (CI950.79-1.28) for PsA to HRadj 1.18 (CI951.07-1.30) for IBD when compared to women without these conditions. No significant increases in the overall risk of MCMs were observed, with the exception of IBD where it reached borderline significance based on sensitivity analyses (ORadj 1.31 (CI951.00-1.71). No evidence of an increased risk of spontaneous loss was observed in women taking azathioprine, mesalazine and sulfasalazine. CONCLUSION: We found no increased risk of spontaneous loss in women with RA, PsA or SpA but a small increase in women with psoriasis or IBD. There was a borderline increased risk of all MCMs in offspring of women with IBD, which should be interpreted cautiously because of potential residual confounding.
Reference Key
openalex_W7201879477 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rachel Charlton, William Tillett, Neil McHugh, Anita McGrogan
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag395
URL
https://doi.org/10.1093/rheumatology/keag395
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.